Literature DB >> 29788077

IRGM Gene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease.

Tracey G Simon1,2,3, Kimberley W J Van Der Sloot2,4, Samantha B Chin1,3, Amit D Joshi2,5,3, Paul Lochhead2,5,3, Ashwin N Ananthakrishnan2,5,3, Ramnik Xavier2,6,3, Raymond T Chung1,2,3, Hamed Khalili2,5,3,7.   

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is an increasingly recognized comorbidity in Crohn's disease (CD), but the mechanisms are poorly understood. Autophagy is a highly conserved process regulating innate immunity that contributes to CD susceptibility. Emerging data suggest that variants in the autophagy-governing IRGM gene may contribute to the accumulation of visceral adipose tissue (VAT) and hepatic fat. Our objective was to characterize the relationship between VAT, IRGM gene variants, and NAFLD risk in patients with CD.
Methods: We included all CD patients in the Prospective Registry in Inflammatory Bowel Disease Study at Massachusetts General Hospital (PRISM) without history of alcohol abuse or liver disease. Hepatic fat was quantified by liver attenuation (LA) on computed tomography, with NAFLD defined by the validated liver:spleen (L:S) ratio. NAFLD severity was estimated by the FIB-4 Index and alanine aminotransferase (ALT). Using logistic regression modeling, we examined the relationship between VAT, autophagy gene variants, and NAFLD risk.
Results: Among 462 patients, 52% had NAFLD. Increasing VAT quartile was associated with reduced LA (mean change, -7.43; 95% confidence interval [CI], -10.05 to -4.81; Ptrend < 0.0001). In the fully adjusted model, patients in the highest VAT quartile had a 2.2-fold increased NAFLD risk (95% CI, 1.21 to 4.14; Ptrend = 0.032) and a 4.2-fold increased risk of ALT>upper limit of normal (ULN) (95% CI, 1.19 to 14.76; Ptrend = 0.017). The relationship between VAT and NAFLD was modified by IRGM variants rs4958847 and rs13361189 (Pinteraction = 0.005 and Pinteraction < 0.001, respectively). Conclusions: In a large CD cohort, VAT was directly associated with prevalent NAFLD, and this relationship was augmented by functionally annotated IRGM variants associated with impaired autophagy.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29788077      PMCID: PMC6230523          DOI: 10.1093/ibd/izy128

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  46 in total

1.  Associations between genetic variants in the IRGM gene and inflammatory bowel diseases in the Korean population.

Authors:  Chang Mo Moon; Dong-Jik Shin; Seung Won Kim; Nak-Hoon Son; Ahram Park; Boram Park; Eun Suk Jung; Eun Soo Kim; Sung Pil Hong; Tae Il Kim; Won Ho Kim; Jae Hee Cheon
Journal:  Inflamm Bowel Dis       Date:  2013-01       Impact factor: 5.325

2.  Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease.

Authors:  Yuichiro Eguchi; Takahisa Eguchi; Toshihiko Mizuta; Yasushi Ide; Tsutomu Yasutake; Ryuichi Iwakiri; Akitaka Hisatomi; Iwata Ozaki; Kyousuke Yamamoto; Yoichiro Kitajima; Yasunori Kawaguchi; Shigetaka Kuroki; Naofumi Ono
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

3.  Risk predisposition for Crohn disease: a "ménage à trois" combining IRGM allele, miRNA and xenophagy.

Authors:  Patrick Brest; Pierre Lapaquette; Baharia Mograbi; Arlette Darfeuille-Michaud; Paul Hofman
Journal:  Autophagy       Date:  2011-07-01       Impact factor: 16.016

4.  Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center.

Authors:  Stefano Bargiggia; Giovanni Maconi; Marco Elli; Paola Molteni; Sandro Ardizzone; Fabrizio Parente; Ivan Todaro; Salvatore Greco; Guendalina Manzionna; Gabriele Bianchi Porro
Journal:  J Clin Gastroenterol       Date:  2003 May-Jun       Impact factor: 3.062

5.  Feasibility of using single-slice MDCT to evaluate visceral abdominal fat in an urban pediatric population.

Authors:  Netta M Blitman; Lindsay Stanton Baron; Robert G Berkenblit; Alan H Schoenfeld; Morri Markowitz; Katherine Freeman
Journal:  AJR Am J Roentgenol       Date:  2011-08       Impact factor: 3.959

6.  Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone.

Authors:  Vernon W Dolinsky; Donna N Douglas; Richard Lehner; Dennis E Vance
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

7.  Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.

Authors:  Achuthan Sourianarayanane; Gaurav Garg; Thomas H Smith; Mujtaba I Butt; Arthur J McCullough; Bo Shen
Journal:  J Crohns Colitis       Date:  2012-11-15       Impact factor: 9.071

8.  Pharmacological promotion of autophagy alleviates steatosis and injury in alcoholic and non-alcoholic fatty liver conditions in mice.

Authors:  Chih-Wen Lin; Hao Zhang; Min Li; Xiwen Xiong; Xi Chen; Xiaoyun Chen; Xiaocheng C Dong; Xiao-Ming Yin
Journal:  J Hepatol       Date:  2013-01-20       Impact factor: 25.083

9.  Autophagy regulates adipose mass and differentiation in mice.

Authors:  Rajat Singh; Youqing Xiang; Yongjun Wang; Kiran Baikati; Ana Maria Cuervo; Yen K Luu; Yan Tang; Jeffrey E Pessin; Gary J Schwartz; Mark J Czaja
Journal:  J Clin Invest       Date:  2009-10-12       Impact factor: 14.808

10.  Lipid-induced hepatic insulin resistance.

Authors:  Thomas Galbo; Gerald I Shulman
Journal:  Aging (Albany NY)       Date:  2013-08       Impact factor: 5.682

View more
  5 in total

Review 1.  Immunity-related GTPase IRGM at the intersection of autophagy, inflammation, and tumorigenesis.

Authors:  Apeksha Bharatgiri Goswami; Dimitrije Karadarević; Natalia Castaño-Rodríguez
Journal:  Inflamm Res       Date:  2022-06-14       Impact factor: 6.986

2.  Meta-analysis: prevalence of, and risk factors for, non-alcoholic fatty liver disease in patients with inflammatory bowel disease.

Authors:  Mohammad Zamani; Shaghayegh Alizadeh-Tabari; Siddharth Singh; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2022-03-11       Impact factor: 9.524

Review 3.  Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases.

Authors:  Rocío Gallego-Durán; Rocío Montero-Vallejo; Douglas Maya-Miles; Ana Lucena; Franz Martin; Javier Ampuero; Manuel Romero-Gómez
Journal:  Front Immunol       Date:  2021-11-24       Impact factor: 7.561

4.  Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Authors:  Austin Lin; Hannah Roth; Adjoa Anyane-Yeboa; David T Rubin; Sonali Paul
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 7.290

Review 5.  Roles of Autophagy-Related Genes in the Pathogenesis of Inflammatory Bowel Disease.

Authors:  Sup Kim; Hyuk Soo Eun; Eun-Kyeong Jo
Journal:  Cells       Date:  2019-01-21       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.